Estrogen patch may ease hot flashes in prostate cancer treatment
NCT ID NCT07466498
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estrogen patches plus an androgen receptor inhibitor against standard hormone therapy plus the same inhibitor. The main goal is to see if estrogen reduces hot flashes after 12 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-SENSITIVE PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread